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Nef is an accessory protein critical for the ability of human and simian immunodeficiency viruses (HIV 
and SIV) to replicate efficiently in their respective hosts. Previous analyses of members of 15 different 
primate lentivirus lineages revealed a link between Nef function and the presence of a vpu gene. In 
particular, Nef proteins of all vpu-containing viruses had lost their ability to downmodulate the T cell 
(TCR-CD3) receptor. Here we examined Nef proteins from eight additional SIV lineages, including 
SIVgor, SIVwrc, SIVolc, SIVgri, SIVdrl, SIVlho, SIVden, and SIVasc, from western lowland gorillas, 
western red colobus monkeys, olive colobus monkeys, grivet monkeys, drills, L'Hoest's monkeys, 
Dent's mona monkeys, and red-tailed monkeys, respectively. We found that except for the nef gene of 
SIVdrl, all of them were efficiently expressed and modulated CD4, major histocompatibility complex 
class I (MHC-I), CD28, CXCR4, and Ii cell surface expression and/or enhanced viral infectivity and 
replication. Furthermore, the Nef proteins of SIVgri, SIVlho, SIVwrc, SIVolc, and SIVgor antagonized 
tetherin. As expected, the Nef protein of SIVgor, which carries vpu, failed to downmodulate CD3, 
whereas those of SIVwrc, SIVgri, SIVlho, and SIVasc, which lack vpu, were capable of performing this 
function. Surprisingly, however, the Nef protein of the vpu-containing SIVden strain retained the ability 
to downmodulate TCR-CD3, whereas that of SIVolc, which does not contain vpu, was unable to 
perform this function. Although the SIVden Vpu is about 20 amino acids shorter than other Vpu 
proteins, it degrades CD4 and antagonizes tetherin. Our data show that there are exceptions to the 
link between the presence of a vpu gene and nef alleles deficient in CD3 modulation, indicating that 
host properties also affect the selective pressure for Nef-mediated disruption of TCR-CD3 signaling. 
Our results are also further evidence that tetherin antagonism is a common function of primate 
lentivirus Nef proteins and that the resistance of human tetherin to Nef represents a relevant barrier to 
cross-species transmission of SIVs to humans.  
 
One feature that distinguishes human and simian immunodeficiency viruses (HIV and SIV) from other 
retroviruses is that they encode several gene products that are not absolutely required for viral spread 
in cell culture but can dramatically alter the efficiency of viral replication and the course of disease 
progression in infected hosts in vivo (reviewed in references 2, 4, 29, 30, 35, and 40). Some of these 
“accessory” genes, i.e., vif, vpr, and nef, are present in the genomes of all primate lentiviruses. In 
contrast, a vpu gene is found only in HIV type 1 (HIV-1), in its chimpanzee and gorilla precursors, 
SIVcpz and SIVgor (18, 24, 44, 58), and in SIVgsn, SIVmus, SIVmon, and SIVden, infecting greater 
spot-nosed, mustached, mona, and Dent's mona monkeys (6, 11-14). Vpu was most likely acquired by 
a precursor of SIVs infecting Cercopithecus monkeys, with subsequent cross-species transmission 
  
and recombination events giving rise to other vpu-containing primate lentiviruses, such as SIVcpz, 
SIVgor, and HIV-1 (5, 51).  
Vpu is expressed from a polycistronic message that also encodes Env during the late stages of the 
viral life cycle and has two major functions. First, it interferes with the transport of newly synthesized 
CD4 to the cell surface by targeting it for proteasomal degradation (8, 36, 62). Second, it promotes 
virion release by antagonizing an alpha interferon (IFN-α)-induced host restriction factor, named 
tetherin (also called BST2, CD317, or HM1.24), that tethers viral particles at the cell surface (41, 60). 
Notably, the multifunctional Nef protein also modulates CD4 cell surface expression and—in some 
lentiviruses—counteracts tetherin (26, 48, 63, 64). In contrast to Vpu, Nef is expressed at high levels 
early following cell infection and downmodulates CD4 by enhancing its internalization and lysosomal 
degradation (reviewed in references 2 and 31). Recently it has been shown that some SIVs that do not 
carry a vpu gene, but also SIVcpz and SIVgor (the vpu-containing precursors of HIV-1), use Nef to 
antagonize tetherin (26, 48, 63, 64). Nef also downmodulates major histocompatibility complex class I 
(MHC-I), CD28, and CXCR4, upregulates MHC-II-associated invariant chain (Ii), and enhances viral 
infectivity and replication (reviewed in references 2, 4, 30, and 35). The importance of the various Nef 
and Vpu activities in vivo is still largely unknown, although there is compelling evidence that a 
combination of functions allows HIV and SIV to replicate and spread efficiently in their respective hosts 
(reviewed in references 2, 4, and 30).  
Vpu and Nef exhibit overlapping functions, and the presence of a vpu gene has been found to 
correlate with changes in Nef function. Specifically, data from a large number of primate lentiviruses 
revealed a striking concordance between the presence of a vpu gene and the inability of Nef to 
downmodulate CD3 (51). In fact, phylogenetic analyses strongly suggest that Nef-mediated 
downmodulation of T cell receptor-CD3 (TCR-CD3) was lost twice during primate lentivirus evolution: 
the first time after a vpu gene was acquired by an ancestor of SIVs now found in Cercopithecus 
monkeys and the second time after SIVrcm recombined with a vpu-containing precursor of 
SIVgsn/mus/mon/den in chimpanzees to become SIVcpz (5, 51).  
The findings described above suggest that Vpu alleviates the need to maintain Nef-mediated TCR-
CD3 downmodulation, possibly because an effective tetherin antagonist may allow efficient viral 
spread in the presence of higher levels of immune activation and thus reduce the selective pressure 
for suppression of T cell activation (28). However, this Nef function has been examined for only a 
fraction of the ∼40 African nonhuman primate species infected with primate lentiviruses (reviewed in 
references 20, 43, and 61). To obtain further insights into primate lentivirus accessory gene function, 
we examined nef alleles from eight additional SIV lineages, including two (SIVgor and SIVden) 
carrying a vpu gene. Surprisingly, one of these (SIVden) carried a vpu gene but retained Nef-mediated 
downregulation of TCR-CD3, while another strain (SIVolc), which lacked vpu, had lost this function. 
These findings suggest that other, yet-to-be-defined viral or host factors also affect the selective 
pressure on Nef-mediated modulation of T cell activation.  
 
 
Materials and methods 
 
nef and vpu alleles and proviral constructs.SIV nef alleles from western red colobus (SIVwrc, 
Piliocolobus badius) and SIVolc from olive colobus (Procolobus verus) monkeys were PCR amplified 
from uncultured primate peripheral blood mononuclear cell (PBMC) DNA (Table 1). SIVwrc nef was 
amplified using the 5′ primer 5SIVwrcNIG (5′-GGATTTTGCTATAAGATGGGTGGAATCTTC-3′) and 
the 3′ primer 3SIVwrcNIG (5′-GCTGAAGCGGCACAAGTGACGCGTTGTTGC-3′). SIVolc nef was 
amplified in 2 rounds of PCR using the 5′ primer 5pSIVolcR1 (5′-GAGACTTACTATCACACCTGTGG-
3′) and 3′ primer 3pSIVolcR1 (5′-GCTTTCGGTTTTGCCCTATAAAAG-3′) in the first round and the 5′ 
primer 5SIVolcNIG (5′-GGATTTTGCTATAAGATGGGATCAATTTGC-3′) and 3′ primer 3SIVolc-MluI 
(5′-CGCCTCTTAAGTGACGCGTATGTTCAG-3′) in the second round of PCR. SIVden, SIVgri, SIVdrl, 
SIVasc, and SIVlho sequences were derived from GenBank (Table 1) and chemically synthesized 
(GenScript, Piscataway, NJ). Molecular cloning of SIVgor has been described previously (58). Splice-
overlap-extension PCR was used to replace the nef gene of HIV-1 (NL4-3-based) proviral constructs 
carrying functional nefs followed by an internal ribosome entry site (IRES) with the different primate 
lentivirus nef genes as described previously (51, 52). The integrity of all PCR-derived inserts was 
  
confirmed by sequence analysis. The control HIV-1 NL4-3-IRES-enhanced green fluorescent protein 
(eGFP) constructs expressing the NL4-3, NA7, and SIVmac239 Nefs or containing a disrupted nef 
gene (nef
−
) have been reported previously (50-52).  
 
Cell culture and virus stocks 
Jurkat and 293T cells were cultured as described previously (51, 52). Briefly, 293T cells were 
maintained in Dulbecco's modified Eagle's medium containing 10% heat-inactivated fetal bovine 
serum. PBMCs from healthy human donors were isolated using lymphocyte separation medium 
(Biocoll separating solution; Biochrom), stimulated for 3 days with phytohemagglutinin (PHA) (1 
μg/ml), and cultured in RPMI-1640 medium with 10% fetal calf serum (FCS) and 10 ng/ml interleukin 2 
(IL-2) prior to infection. To generate viral stocks, 293T cells were either transfected with the proviral 
HIV-1 constructs alone (to measure viral infectivity or replication) or cotransfected with a plasmid 
(pHIT-G) expressing the vesicular stomatitis virus G protein (VSV-G) for flow cytometric analyses (51, 
52). The medium was changed after overnight incubation, and virus was harvested 24 h later. 
Residual cells in the supernatants were pelleted, and the supernatants were stored at −80°C. Virus 
stocks were quantified using a p24 antigen capture assay provided by the NIH AIDS Research and 
Reference Reagent Program.  
 
Transduction and flow cytometry 
Jurkat T cells, THP1 cells, or PBMCs were transduced with HIV-1 (NL4-3) constructs coexpressing 
eGFP and various nef alleles, and CD4, TCR-CD3, MHC-I, CD28, CXCR4, CD25, CD69, Ii, and eGFP 
expression was measured as described previously (51, 52). For quantification of Nef-mediated 
modulation of specific surface molecules, the levels of receptor expression (red fluorescence) were 
determined for cells expressing a specific range of eGFP. The extent of downmodulation (n-fold) was 
calculated by dividing the mean fluorescence intensity (MFI) obtained for cells infected with the nef
−
 
NL4-3 control viruses by the corresponding values obtained for cells infected with viruses 
coexpressing Nef and eGFP.  
 
Western blot 
To monitor Vpu expression, 293T cells were transfected with 5 μg of vector DNA coexpressing eGFP 
and AU-1-tagged Vpus or proviral constructs. Two days posttransfection, cells were harvested and 
lysed in RIPA (1% NP-40, 0.5% Na-DOC, 0.1% SDS, 0.15 M NaCl, 50 mM Tris-HCl [pH 7.4], and 5 
mM EDTA), and cell lysates were separated in 16% SDS-polyacrylamide (PAA) gels in a Tris-Tricine 
buffer system. To reduce the oligomerization of Vpu, the SDS concentration in the sample buffer was 
increased to 1%. After gel electrophoresis, proteins were transferred onto polyvinylidene difluoride 
(PVDF) membranes and probed with AU-1 antibody (MMS-130P), followed by enhanced 
chemiluminescence detection.  
 
CD8 fusions containing the cytoplasmic domain of the CD3-ζ chain 
The generation of a vector expressing CD8 fused to the cytoplasmic domain of the human CD3-ζ 
chain has been described previously (57). To replace the human CD3-ζ gene with the simian version, 
the rhesus macaque CD3-ζ gene (GenBank accession number DQ437670) was chemically 
synthesized (GenScript). Subsequently, splice-overlap-extension PCR using the primers p5-huCD8 
(5′-CCTTCTAGACTAAAGATGGCCTTACCAGTG-3′) and p3-huCD8 (5′-
GCTGAACTTCGCTCTGTGGTTGCAG-3′) and primers p5-rhζ (5′-
CTGCAACCACAGAGCGAAGTTCAGC-3′) and p3-rhζ (5′-
GATCCGACGCGTTTAGCGAGGGGGCAG-3′) was performed to fuse the gene encoding the 
extracellular part of human CD8 to the rhesus-derived sequence encoding the CD3-ζ cytoplasmic 
domain. The PCR-derived fragment was verified by sequence analysis. To assess species-specific 
effects of Nef on CD3, 293T cells were cotransfected with NL4-3-based proviral constructs 
coexpressing Nef and eGFP together with pCGCG vectors expressing CD8 fusion containing the 
human or macaque CD3-ζ chains. For quantification of CD8 surface expression, cells were stained 
  
with phycoerythrin (PE)-conjugated monoclonal antibody RPA-T8 (BD Biosciences). Fluorescence 
intensity on eGFP-positive cells was measured by flow cytometry and compared to that on cells 
transfected with a nef-defective HIV-1 control construct (100%).  
 
NFAT assay 
Jurkat cells stably transfected with an NFAT-dependent reporter gene vector (17) were either left 
uninfected or transduced with HIV-1 Nef-eGFP constructs expressing various nef alleles. Except for 
those cells used as controls, cultures were treated with PHA (1 μg/ml; Murex). Luciferase activity was 
measured and n-fold induction determined by calculating the ratio of measured relative light units 
(RLU) of treated samples to that of untreated samples, as described previously (50).  
 
Viral infectivity. 
Virus infectivity was determined using P4-CCR5 and TZM-bl cells as described previously (39). Briefly, 
the cells were sown out in 96-well dishes in a volume of 100 μ1 and infected after overnight incubation 
with virus stocks, containing 1 ng of p24 antigen, produced by transfected 293T cells. Two days 
postinfection, viral infectivity was detected using the Gal screen kit from Tropix as recommended by 
the manufacturer. β-Galactosidase activities were quantified as relative light units per second using 
the Orion microplate luminometer.  
 
Virus spread in PBMCs 
To assess the ability of Nef to promote viral spread, 2 × 10
5
 prestimulated PBMCs per well were sown 
in 48-well dishes and infected with 293T cell-derived virus stocks containing 1 ng of p24 antigen. 
Aliquots of the cells were obtained at 3, 5, and 7 days postinfection, and the number of virally infected 
eGFP
+
 cells was determined by flow cytometric analysis.  
 
CD4 degradation 
To determine the effect of Vpu on CD4 cell surface expression, 293T cells were transfected by the 
calcium phosphate method in triplicate with 1 μg of a CD4 expression vector and 5 μg of pCGCG 
eGFP/Vpu constructs expressing eGFP alone or together with Vpu. Two days posttransfection, CD4 
expression was examined by fluorescence-activated cell sorting (FACS) analysis, as described 
previously (48).  
 
Tetherin antagonism 
To determine the capability of Nef and Vpu to antagonize tetherin, 293T cells were seeded in six-well 
plates and transfected with 2 μg of NL4-3 ΔVpu/ΔNef/eGFP or 500 ng Vpu or Nef expression plasmid 
and different dilutions of tetherin expression vectors (100, 50, and 25 ng). A pCGCG vector expressing 
eGFP only was used to equalize the DNA concentrations. At 2 days posttransfection, supernatants 
were harvested and analyzed for the release of p24 antigen and infectious virus as described 
previously (48).  
 
Phylogenetic analysis 
Phylogenetic trees of Nef amino acid sequences were inferred by the Bayesian method (23) 
implemented in the MrBayes software program, v3.2.1, using a mixed model (45) and gamma 
distributed rates at sites with 1 million generations. The average standard deviation of split frequencies 
was 0.007. Virus strains used for analysis were HIV-1 NL4-3, HIV-1 NA7, SIVcpz GAB2, SIVcpz 
TAN1, SIVrcm15, SIVrcm GB1, HIV-2 BEN, HIV-2 60415k2, SIVsmm FFm1, SIVagm TAN1, SIVagm 
TAN18, SIVagm SAB1, SIVmon NG1, SIVmon CML1, SIVmus CMS1085, SIVgsn CM166, SIVdeb 
  




The activities of nef alleles were compared using a two-tailed Student t test. The PRISM software 




In this work, we studied nef alleles from eight SIV lineages that have not been previously examined: 
SIVgor from the western lowland gorillas (Gorilla gorilla gorilla), SIVwrc from western red colobus 
monkeys (Piliocolobus badius), SIVolc from olive colobus monkeys (Procolobus verus), SIVgri from 
grivet monkeys (Chlorocebus aethiops), SIVdrl from drills (Mandrillus leucophaeus), SIVlho from 
L'Hoest's monkeys (Cercopithecus lhoesti lhoesti), SIVden from a Dent's mona monkey 
(Cercopithecus denti), and SIVasc from a red-tailed monkey (Cercopithecus ascanius schmidti) 
(summarized in Table 1). Phylogenetic examination confirmed their authenticity (Fig. 1). Together with 
30 SIV and HIV nef genes from 15 different primate species investigated in previous studies (39, 51), 
they represent the majority of primate lentivirus lineages currently characterized (summarized in Table 
S1 in the supplemental material). As expected from published data (12-14, 22, 32, 58), SIVgor Nef 
clustered with those of HIV-1 and SIVcpz, SIVgri Nef with SIVtan and SIVsab, infecting other African 
green monkey (AGM) species, and SIVdrl with SIVlho and SIVsun (Fig. 1). The Nef amino acid 
sequences of SIVwrc and SIVolc found in western red and olive colobus monkeys also clustered 
together but were only distantly related to one another and to those of other SIVs. The SIVasc Nef was 
most closely related to those of SIVsyk. Interestingly, Nef of the vpu-containing SIVden strain was 
more closely related to Nefs of SIVdeb strains (which do not have vpu) than to Nefs derived from 
SIVgsn, SIVmus, and SIVmon, which also encode Vpu (14) (Fig. 1). Altogether, the Nef amino acid 
sequences were highly variable, and the lengths of the open reading frames ranged from 558 (SIVolc) 
to 747 (SIVden) bp (summarized in Table 1).  
To assess the potencies of SIVgor, SIVwrc, SIVolc, SIVgri, SIVdrl, SIVlho, SIVden, and SIVasc Nefs in 
downmodulating CD3, CD4, CD28, CXCR4, and MHC-I, we transduced human PBMCs with proviral 
HIV-1 NL4-3 constructs coexpressing the various Nef proteins and eGFP and analyzed them by flow 
cytometry. Most Nef proteins downmodulated CD4, CD28, CXCR4, and MHC-I. The exception was the 
SIVdrl Nef protein, which did not downmodulate CXCR4 and MHC-I and had only very modest effects 
on CD4 and CD3 (Fig. 2). In agreement with this poor activity, the SIVdrl Nef was not expressed at 
detectable levels (data not shown). Like the HIV-1 NL4-3 and NA7 nef alleles, that of SIVgor failed to 
downmodulate TCR-CD3, although it was capable of modulating CD4, CD28, CXCR4, and MHC-I 
(Fig. 2). The SIVmac239, SIVwrc, SIVgri, SIVlho, SIVden, and SIVasc Nefs downmodulated TCR-CD3 
as well as other receptors investigated (Fig. 2). Surprisingly, the nef allele of the Vpu-encoding SIVden 
was capable of downmodulating CD3 (2.59 ± 0.38-fold), albeit less efficiently than those of SIVmac, 
SIVwrc, SIVgri, SIVlho, and SIVasc (3.86-fold to 5.54-fold) (Fig. 2). It was also unexpected that the 
SIVolc Nef protein did not downmodulate TCR-CD3 (Fig. 2), since it is derived from a virus that does 
not encode Vpu (28). The SIVolc nef open reading frame is substantially shorter (558 bp) than those 
of other primate lentiviruses (between 621 and 792 bp), including that of its closest relative, SIVwrc 
(702 bp) (Table 1). To exclude the possibility that the small size and the lack of CD3 modulation were 
allele specific, we analyzed a total of eight different SIVolc nef genes derived from two independent 
PCRs. All had the same size, and none of them modulated TCR-CD3 cell surface expression (data not 
shown).  
Previous studies showed that the capability of different primate lentivirus Nefs to downmodulate CD4, 
CD3, CXCR4, and MHC-I from the cell surface is usually species independent (21, 50, 51). However, 
we considered the possibility that the SIVolc Nef may downmodulate TCR-CD3 in simian but not 
human cells, since the cytoplasmatic domain of the CD3-ζ chain that interacts with Nef differs in four to 
six amino acid positions in this region (Fig. 3 A). In particular, we wondered whether a two-amino-acid 
(NQ) insertion may influence Nef binding since it is located in a region shown to interact with the 
SIVmac239 Nef protein (49). We thus analyzed CD8-CD3-ζ fusion proteins containing the 
  
cytoplasmatic domains of the human and rhesus TCR-ζ chains. We selected this approach since 
SIVmac and HIV-2 Nefs have been shown to interact specifically with the cytoplasmatic domain of 
CD3-ζ and this interaction is sufficient to cause downmodulation of TCR-CD3 and other receptors 
fused to this domain (49, 57). The rhesus CD3-ζ sequence was selected because rhesus macaques 
and olive colobus monkeys belong to the same family (Cercopithecidae) and because the CD3-ζ 
sequence of the olive colobus is not available. 293T cells were cotransfected with constructs 
expressing Nef and the CD8-CD3-ζ fusions, and the cell surface expression of CD8 was measured by 
flow cytometric analysis 2 days later. We found that SIVmac239 Nef reduced the surface expression of 
CD8 fused to both human- and rhesus-derived CD3-ζ cytoplasmic regions whereas SIVolc and HIV-1 
Nefs were generally inactive (Fig. 3B and C). Thus, the inability of SIVolc Nefs to downmodulate TCR-
CD3 is not limited to the human ortholog.  
It has been shown that Nef proteins which downmodulate TCR-CD3 suppress T cell activation 
whereas those that do not perform this function have little inhibitory effect or may even render the 
infected cells hyperresponsive to stimulation (3, 17, 51). To assess whether this was also true for the 
newly analyzed SIV Nefs, we measured the cell surface expression levels of the early activation 
marker CD69 on virally infected PBMCs upon PHA stimulation. As shown in Fig. 4 A, all Nef proteins 
that downmodulated TCR-CD3 suppressed the induction of CD69 expression. Consistent with its 
lower activity in CD3 modulation, the SIVden Nef protein was less effective in inhibiting CD69 
induction than all remaining Nefs that downmodulate CD3 (Fig. 4A). We also transduced Jurkat T cells 
stably transfected with the luciferase reporter gene under the control of an NFAT-dependent promoter 
(16) with the proviral HIV-1 eGFP-Nef constructs and examined their responsiveness to activation. T 
cells infected with a nef-defective HIV-1 construct showed about 3-fold enhanced levels of NFAT 
activity upon PHA stimulation compared to mock-infected cells (Fig. 4B). This increase was further 
enhanced by expression of NL4-3, NA7, SIVgor, and SIVolc Nefs that lack the CD3 downmodulation 
function (Fig. 4B). In contrast, SIV Nefs that remove TCR-CD3 from the cell surface usually 
suppressed the induction of NFAT-dependent luciferase activity (Fig. 4B). Nef-mediated suppression 
of T cell activation by downmodulation of TCR-CD3 was also associated with reduced levels of 
apoptotic virally infected T cells (Fig. 4C). Notably, relatively modest efficiencies of CD3 
downmodulation were sufficient to suppress NFAT activation and apoptosis (Fig. 4B and C, right 
panels).  
Previous data have shown that Nef proteins from HIV-1 and HIV-2 upregulate the expression of the 
invariant chain (Ii) at the cell surface, most likely to interfere with MHC-II antigen presentation (52, 55). 
To determine whether other primate lentiviral Nefs also modulate Ii, we used the human monocytic 
leukemia THP-1 cell line, which shares many properties with monocyte-derived macrophages and 
expresses high levels of MHC-II (59). THP-1 cells infected with proviral constructs expressing the HIV-
1 NL4-3 and NA7, as well as the SIVgor, SIVwrc, SIVgri, SIVlho, and SIVasc Nefs, showed about 8- to 
12-fold-enhanced levels of Ii surface expression (Fig. 5 A and B). In comparison, the SIVmac239, 
SIVolc, and SIVden nef alleles had only modest effects on Ii, and the SIVdrl Nef was inactive. Our 
finding that several highly divergent SIV Nefs were as active as those of HIV-1 in modulating Ii surface 
expression supports that the capability to modulate MHC-II-restricted antigen presentation is a 
conserved property of primate lentiviruses.  
In addition to manipulating the functions of T cells and antigen-presenting cells (APCs), Nef also 
directly enhances the infectivity of viral particles (1, 10, 38, 39). To assess the abilities of the various 
SIV Nef proteins to enhance virion infectivity, we infected P4-CCR5 indicator cells (16) with virus 
stocks derived from 293T cells transiently transfected with the different proviral constructs. The results 
showed that the NL4-3, NA7, SIVmac, SIVgor, SIVwrc, SIVolc, and SIVden Nefs enhanced virion 
infectivity between 9- and 15-fold (Fig. 6). In comparison, the SIVasc and SIVdrl Nefs were inactive, 
and the SIVgri and SIV lho Nefs showed an intermediate phenotype. It is known that the abilities of 
Nef to enhance virion infectivity and to stimulate viral replication in primary T cells do not correlate with 
one another but represent independent Nef functions (34). Thus, we next investigated whether the 
different SIV nef alleles promote viral spread in human PBMCs. We found that all Nef proteins 
enhanced viral spread, albeit with different efficiencies (Fig. 7 A). The HIV-1 NA7, SIVmac239, SIVgor, 
SIVolc, and SIVlho Nefs were highly effective (Fig. 7B). In comparison, the SIVdrl, SIVden, and 
SIVasc Nefs were poorly active in the PBMC assay, and the NL4-3, SIVwrc, and SIVgri nef alleles 
showed an intermediate phenotype.  
Recently it has been shown that some SIVs that do not possess a vpu gene, but also SIVcpz and 
SIVgor, which carry vpu, use their Nef proteins to antagonize the host restriction factor tetherin (BST-
  
2) (26, 48, 64). Since it is not known to what extent primate lentiviruses use Nef to counteract tetherin, 
we cotransfected 293T cells with HIV-1 NL4-3 constructs containing defective vpu and nef genes as 
well as pCG vectors expressing AU-1-tagged versions of different Nef proteins at different doses of 
human or African green monkey tetherin. We selected these two tetherin variants because those of 
other primate hosts, including those of the SIVs analyzed in the present study, are not available for 
analysis. None of the Nef proteins analyzed was capable of antagonizing human tetherin (Fig. 8, left). 
This was expected, because the human protein contains a deletion in its cytoplasmic domain that 
renders it resistant to Nef (26, 48, 64). In contrast, SIVsab Nef (26, 27, 64), as well as the Nef proteins 
of SIVgri, SIVlho, SIVolc, and SIVwrc, increased the release of infectious virions in the presence of 
AGM tetherin (Fig. 8, right). Consistent with previous results, the SIVmac239 and SIVgor Nefs were 
only poor antagonists of AGM tetherin, although they counteract the tetherin variants found in their 
own macaque and gorilla hosts (48, 64). Such species specificity may also explain why the SIVasc Nef 
did not antagonize AGM tetherin. Altogether, these data show that tetherin antagonism by Nef is a 
common feature of primate lentiviruses.  
One possible explanation for why the SIVden Nef protein has not lost its TCR-CD3 downmodulation 
function is that its Vpu protein is prematurely truncated (Fig. 9 A) and may thus be unstable and/or 
nonfunctional. To assess this, we first examined the expression of an AU1-tagged version of the 
SIVden Vpu protein. For comparison, we also generated a C-terminally truncated mutant NL4-3 Vpu 
(E65*) protein. Western blot analysis showed that the SIVden and NL4-3 E65* Vpus were efficiently 
expressed (Fig. 9B). To determine whether these Vpus prevented cell surface expression of CD4, we 
cotransfected 293T cells with vectors coexpressing Vpu and eGFP (or eGFP alone for the control) 
together with a human CD4 expression construct. In the absence of Vpu, cells coexpressed CD4 and 
eGFP at high and correlating levels (Fig. 9C). However, upon coexpression of the wild-type NL4-3 and 
SIVden Vpus, CD4 surface expression was strongly decreased. In contrast, the NL4-3 E65* Vpu 
protein had only a modest effect (Fig. 9C). Quantitative analyses showed that the SIVden Vpu protein 
blocked CD4 cell surface expression almost entirely (Fig. 9D). Thus, the C-terminal truncation does 
not impair the capability of the SIVden Vpu to degrade the CD4 receptor.  
Next, we examined whether the highly divergent SIVden Vpu protein antagonizes tetherin. Since the 
tetherin variant found in Dent's mona monkeys, the natural host of SIVden, is not available, we used 
tetherins derived from humans, chimpanzees (CPZ), AGMs, and rhesus macaques (RMs). To test 
whether the SIVden and control Vpus were capable of counteracting tetherins from these species, we 
measured infectious virus yields from 293T cells following cotransfection of a vpu-deleted (ΔVpu) HIV-
1 proviral construct with Vpu and tetherin expression plasmids. In agreement with the results of a 
previous study (63), our data showed that the SIVden Vpu protein efficiently counteracted monkey 
tetherins but was inactive against the human- and CPZ-derived restriction factors (Fig. 9E). In 
contrast, the NL4-3 control Vpu protein had the opposite phenotype, and the truncated NL4-3 E65* 
Vpu mutant was largely inactive. These results are in agreement with published data showing that Vpu 
antagonizes tetherin in a species-specific manner (19, 37, 48, 63). Moreover, SIVden Vpu, despite its 





In the present study, we expanded previous functional analyses of nef and vpu alleles from diverse 
primate lentiviruses (21, 26, 39, 48, 51, 52, 63, 64). We showed that the Nef proteins of SIVgor, 
SIVwrc, SIVolc, SIVgri, SIVlho, SIVden, and SIVasc modulate the surface expression of human CD4, 
CD28, MHC-I, and Ii molecules and enhance viral spread and infectivity. Consistent with previous data 
(39, 51), these results reinforce the view that nef alleles from highly divergent primate lentiviruses do 
not require adaptive changes to perform most of their activities in human cells. The exception is Nef-
mediated antagonism of tetherin. It has been shown previously that the Nef proteins of SIVagm, 
SIVsmm, SIVmac, SIVcpz, and SIVgor antagonize the tetherins of their particular hosts but are all 
inactive against human tetherin because of a unique five-amino-acid deletion in the cytoplasmic 
domain (26, 48, 64). Here we have shown that the SIVwrc, SIVolc, SIVgri, and SIVlho Nefs also 
counteract simian tetherins but have no activity against the human restriction factor (Fig. 9). It is thus 
clear that Nef-mediated tetherin antagonism is a fundamental property of primate lentiviruses (see 
Table S1 in the supplemental material), and the resistance of human tetherin to primate lentivirus Nefs 
  
seems to represent a significant barrier to zoonotic transmissions. Unfortunately, this hurdle is not 
insurmountable, since HIV-1 and HIV-2 managed to switch from Nef to Vpu or Env, respectively, to 
regain anti-tetherin activity in the new human host (reviewed in references 15, 29, and 47).  
It has been reported that some primate lentiviruses, such as SIVagm, did not evolve tetherin 
antagonists because they do not induce chronic immune activation, and thus expression of type I 
interferons and tetherin, in their natural simian hosts (33). In contrast, we and others have shown that 
the SIVagm and SIVsmm Nef proteins are tetherin antagonists (26, 48, 64), although these viruses 
cause neither chronic inflammation nor disease in their natural African green monkey and sooty 
mangabey hosts (reviewed in references 42 and 54). Moreover, as summarized in Table S1 in the 
supplemental material, it is now clear that most primate lentiviruses have evolved tetherin antagonists, 
suggesting that they encounter this restriction factor during natural infection. One possible explanation 
for this seeming controversy is that primate lentiviruses that induce high levels of inflammation may 
need particularly effective tetherin antagonists. In accordance with this, the Vpu proteins of pathogenic 
HIV-1 strains seem to be more effective in counteracting tetherin than the Nef proteins of the 
nonpathogenic SIVagm and SIVsmm strains (26, 33, 48, 63, 64). However, it should be noted that the 
efficiency of tetherin antagonism of primate lentiviruses in primary cells and its relevance in vivo (46) 
remain largely unknown, since most data thus far are limited to transient transfection assays.  
To date, nef alleles from all groups of HIV-1 (M, N, O, and P), HIV-2 groups A and B, and about 20 
different SIVs have been functionally analyzed. The results from these studies have shown that some 
Nef activities, such as downmodulation of CD4 and MHC-I, as well as enhancement of virion infectivity 
and stimulation of virus replication, are conserved among most or all primate lentiviruses (summarized 
in Table S1 in the supplemental material). These Nef functions facilitate viral immune evasion and 
promote viral spread directly. Thus, it seems plausible that they are always advantageous for the virus 
and thus are generally preserved. In contrast, the HIV and SIV Nef proteins show fundamental 
differences in activities affecting the responsiveness of virally infected T cells to stimulation via the 
TCR-CD3 complex (see Table S1). Most primate lentivirus Nefs efficiently downmodulate both TCR-
CD3 and the CD28 costimulatory factor from the surfaces of virally infected T cells to prevent their 
interaction with antigen-presenting cells and responsiveness to stimulation (Fig. 4) (3, 51). The 
advantage for the virus is most likely a longer time period of virus production due to the suppression of 
apoptosis and thus an increased life span of the infected cells, as well as a suppression of overall 
immune activation (28). In contrast, the Nef proteins of HIV-1 and its direct SIV progenitors have no 
effect on CD3 and are poorly active in CD28 downmodulation (3, 51). As a consequence, these Nef 
proteins do not suppress the stimulation of virally infected CD4
+
 T cells via the TCR-CD3 complex (3, 
17, 51). The acquisition of a vpu gene seems to reduce the selective pressure for suppression of T cell 
activation, because its presence was associated with the inability of Nef to downmodulate TCR-CD3 in 
all primate lentiviruses previously analyzed (51). Furthermore, phylogenetic analyses indicate that the 
SIV precursors of HIV-1 lost this Nef function twice when they acquired a vpu gene (51). Vpu, as an 
effective virion release factor and tetherin antagonist, may thus have favored the emergence of viruses 
that enhance rather than block T cell activation and thus proviral transcription because it allows them 
to cope with the higher activation of the host immune system (reviewed in reference 28). Differences in 
Nef-mediated downmodulation of TCR-CD3 and CD28 may help primate lentiviruses to compensate 
for species-specific differences in the responsiveness of T cells to activation and thus in viral gene 
expression. Since different primate species may respond to SIV infection differently (7, 25, 53) and the 
host environment may also affect Nef function (9), it is perhaps not surprising that the presence of vpu 
and lack of Nef-mediated TCR-CD3 downmodulation are not generally linked. A strong inflammatory 
response of Dent's mona monkeys to SIV infection may explain why this virus maintained the 
capability to downmodulate TCR-CD3 from the cell surface (albeit with relatively low efficiency), 
although it expresses a functional Vpu protein. On the other hand, SIVolc may have lost its capability 
to remove CD3 from the surface to achieve levels of T cell activation sufficient for viral replication. 
Studies of these viruses in their natural primate hosts will be required to address these possibilities.  
Early data suggested that the vpu gene originated from a common ancestor of SIVgsn, SIVmus, and 
SIVmon after the divergence of SIVsyk and SIVdeb and was subsequently transferred to chimpanzees 
and humans by zoonotic viral transmissions and a recombination event (5, 51). However, the finding 
that the vpu-containing SIVden strain is more closely related to SIVdeb (which does not carry a vpu 
gene) than to SIVgsn, SIVmus, and SIVmon (Fig. 1) (14) is at odds with this hypothesis. It remains 
elusive whether SIVs found in some Cercopithecus species lost their vpu gene during evolution (14) or 
whether SIVden acquired its vpu gene more recently by recombination with an as yet unknown SIV 
strain, and both possibilities seem plausible.  
  
The current data add to a comprehensive set of Nef proteins that differ in their capability to 
downmodulate TCR-CD3 (see Table S1 in the supplemental material). Unfortunately, inspection of 
their alignment does not allow pinpointing of the sequence variations responsible for the differential 
capability of primate lentiviral Nef proteins to modulate TCR-CD3. As shown in Fig. S1, the Nef amino 
acid sequences are highly divergent, and the two groups that differ in their CD3 downmodulation 
capabilities do not exhibit any striking differences. Previous analyses of the SIVmac239 Nef protein 
have shown that the CD3 downmodulation activity maps to the central core region of Nef and involves 
cooperative binding of Nef and CD3-zeta to bind AP-2 (49, 57). In agreement with these data, we 
identified amino acid substitutions in the core region of SIVsmm Nef that selectively affect the CD3 
downmodulation function (J. Schmökel and F. Kirchhoff, unpublished data). However, the critical 
residues are not conserved in other SIV Nefs that downmodulate TCR-CD3. Furthermore, changes in 
the flexible N-proximal region of the SIVdeb Nef protein also selectively disrupt CD3 downmodulation 
(data not shown). Thus, similarly to downmodulation of MHC-I (56), the effect on CD3 may involve 
different domains in various primate lentivirus Nef proteins.  
Substantial progress has been made in understanding the functions of the primate lentivirus Vpu and 
Nef proteins, and the results suggest that differences in the functions of these two accessory proteins 
may play relevant roles in the pathogenesis and spread of HIV-1 (reviewed in references 2, 4, 28-30, 
and 35). Nonetheless, our knowledge is still far from complete. For some SIV strains, only single nef or 
vpu alleles are available for analysis. Another caveat is that most studies were performed in human-
derived cells because primary cells of the natural hosts of most SIVs are not available for 
experimentation. These analyses have shown that most Nef functions and Vpu-mediated degradation 
of CD4 are largely species independent (39, 51). However, the capability of the viral accessory 
proteins to antagonize host restriction factors is usually highly specific, and some functions may be 
missed in human-derived cells (19, 26, 37, 41, 48, 63, 64). Thus, the analysis of primary SIV strains in 
relevant target cells from their respective host species, as well as studies in primate models of 
pathogenic and nonpathogenic SIV infection, is required to better understand the relevance of specific 
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Tables and Figures 
 
 
Figure 1. Evolutionary relationships among primate lentivirus Nef sequences. Nef alleles newly 
analyzed in the present study are highlighted with yellow boxes, and those of vpu-containing viruses 
are underlined. Nef alleles that downmodulate CD3 are shown in green, those that are selectively 
defective in CD3 downmodulation in red, and those that are generally poorly functional in blue. The 
tree was midpoint routed and inferred by the Bayesian method (23) implemented in MrBayes v3.2.1 as 
described in Methods. Numbers on branches are percent estimated posterior probabilities. Only those 









Figure 2.  Modulation of cellular receptors by primate lentivirus nef alleles. PBMCs were transduced 
with HIV-1 NL4-3 Nef-eGFP constructs coexpressing the indicated nef alleles and eGFP and assayed 
for surface expression of CD4, CD3, CD28, MHC-I, and CXCR4. The HIV-1 NL4-3, NA7, and 
SIVmac239 nef alleles have been functionally characterized in previous studies (3, 50) and are shown 
for comparison. Nef-mediated modulation of the indicated cellular receptors was calculated by dividing 
the mean fluorescence intensity obtained on cells coexpressing eGFP and the different nef alleles by 
the mean fluorescence obtained for cells transduced with a control HIV-1 construct containing a 
disrupted nef gene. The same ranges of eGFP expression were used in all calculations. Values give 







Figure 3.  Interaction of Nef with the human and rhesus macaque TCR-CD3-ζ chains. (A) Alignment of 
the human CD3 sequence with those of other primate species. Dots represent amino acid identity; 
dashes represent gaps. The two domains previously proposed to interact with Nef (49) are indicated. 
(B) Expression levels of CD8 fusions containing CD3-ζ cytoplasmic domains of human (hu) or rhesus 
macaque (rh) origin. 293T cells were transiently cotransfected with pCGCG vectors expressing eGFP 
alone (control) or together with CD8-CD3-ζ fusion proteins and proviral HIV-1 constructs containing 
the nef alleles or a disrupted nef gene (nef*). The cells were stained for CD8 at 2 days 
posttransfection. (C) Levels of CD8 cell surface expression in the presence of the indicated nef alleles 
compared to those measured in the absence of Nef (100%). Values give averages ± SD derived from 
two independent experiments. Similar results were obtained with 5 different SIVolc nef alleles.  
  
Figure. 4. Modulation of T cell activation and apoptosis by primate lentiviral nef alleles. (A) CD69 
expression levels on PBMCs infected with HIV-1 constructs coexpressing eGFP and the indicated nef 
alleles are shown relative to those measured on T cells transduced with the nef defective (nef−) 
control virus (100%). (B) Analysis of Jurkat cells stably transfected with an NFAT-dependent reporter 
gene following transduction with the indicated HIV-1 Nef-eGFP constructs and subsequent stimulation 
with PHA. “Mock” specifies uninfected control cells. (C) Percentages of Annexin V
+
 apoptotic cells in 
uninfected cultures or in HIV-1-infected cells expressing eGFP alone (nef−) or the indicated nef alleles 
are indicated. Values shown in the left in panels A to C give averages ± SD derived from three 
independent experiments. The right panels indicate the correlation between the levels of CD69 
expression (A), PHA-induced levels of NFAT-dependent luciferase activities (B), or the percentages of 
apoptotic eGFP
+
 HIV-1-infected PBMCs and the efficiency of Nef-mediated CD3 downmodulation (C) 














Figure 5. Modulation of the MHC-II-associated invariant chain (Ii) by SIV nef alleles. (A) Surface 
expression of Ii on THP-1 cells infected with HIV-1 Nef-eGFP constructs containing the indicated intact 
nef gene or a disrupted one. Ranges of eGFP expression levels used to calculate receptor modulation 
are indicated by black bars. (B) Quantitative assessment of Nef-mediated upmodulation of Ii on THP-1 




Figure 6. Enhancement of viral infectivity by primate lentivirus nef alleles. Infectivity of HIV-1 NL4-3 
variants containing the indicated nef alleles. P4-CCR5 reporter cells were infected with HIV-1 NL4-3 
IRES-eGFP constructs containing the indicated nef genes or a disrupted nef allele. Infections were 
carried out in triplicate with two different virus stocks containing 1 ng p24 antigen. Infectivity is shown 
relative to that of the recombinant virus containing the NL4-3 nef allele. Similar results were obtained 








Figure 7. Enhancement of viral replication by primate lentivirus nef alleles. (A) Replication kinetics of 
recombinant NL4-3 variants containing the indicated nef alleles in PBMCs. Infections were carried out 
using virus stocks containing 1 ng p24 antigen. The numbers of virally infected GFP
+
 cells were 
measured by flow cytometric analysis. Similar results were obtained in two independent experiments. 
(B) Cumulative numbers of HIV-1-infected GFP
+
 cells detected in PBMC cultures at days 3, 5, 7, and 






Figure 8. Tetherin antagonism by primate lentivirus Nef proteins. Infectious virus yield from 293T cells 
cotransfected with the proviral HIV-1 NL4-3 ΔVpu ΔNef construct (48) containing disrupted vpu and 
nef genes (2 μg) and pCGCG vectors expressing the indicated nef alleles (500 ng), in combination 
with the indicated quantities of plasmids expressing the HU or AGM tetherins. Shown are average 
values derived from triplicate infections of TZM-bl indicator cells. All values are shown relative to those 










Figure 9. Functional activity of the SIVden vpu allele. (A) Alignment of HIV-1 and SIV Vpu sequences. 
The hydrophobic transmembrane (TM) domain, the central charged region, the positions of two serine 
phosphorylation sites, and a β-turn motif in the NL4-3 Vpu protein are indicated. Dashes indicate gaps 
introduced to optimize the alignment. (B) Expression of the HIV-1 and SIVden Vpu proteins. 293T cells 
were transfected with expression plasmids encoding the indicated AU1-tagged Vpu proteins and 
eGFP. Mock-transfected cells were used as negative controls; β-actin and eGFP expression levels 
were analyzed to control for loading and transfection efficiency (lower panels). (C) Suppression of CD4 
surface expression by the SIVden Vpu. FACS analysis of 293T cells cotransfected with a CD4 
expression vector and pCGCG plasmids expressing eGFP alone (vector) or together with the indicated 
vpu alleles is shown. (D) Levels of CD4 cell surface expression relative to those measured in cells 
transfected with the eGFP-only control vector (100%). Shown are average values ± SD derived from 
three experiments. (E) Effects of the NL4-3, NL4-3 E65*, and SIVden Vpu on infectious virus release 
in the presence of human (HU), chimpanzee (CPZ), AGM, or rhesus macaque (RM) tetherin. 293T 
cells were cotransfected with HIV-1 ΔVpu NL4-3 (2 μg) and pCGCG vectors expressing eGFP alone 
or together with Vpu (500 ng) and the indicated amounts of tetherin expression construct (25, 50, or 
100 ng). Viral supernatants were obtained 2 days later and used to measure the quantity of infectious 
HIV-1 in the culture supernatants by infecting TZM-bl indicator cells. Shown are average values ± SD 
(n = 3) of infectious virion yield relative to those obtained in the absence of the tetherin expression 
vector (100%). The results were confirmed in two independent experiments.  
 
 
